Elan Drug Technologies, a business unit of Elan Corporation, plc received the top award for Technology Innovation at the Drug Delivery Partnership (DDP) meeting for its NanoCrystal technology, which was voted as the most successful drug delivery technology innovation. The technology was designed to overcome issues associated with poor water solubility. Ten years since its first filing with the FDA, products using this technology are now marketed in over 100 territories worldwide and have achieved product in-market sales of more than $7.5B.
“We are delighted to accept this award, as voted by our peers, for our NanoCrystal technology platform,” announced Shane Cooke, executive vice president and head of Elan Drug Technologies. “This technology continues to be a major commercial success for our licensees. We strive to continue developing technologies and products that are innovative, unique and market relevant so as to provide true patient benefit to our clients.”
The award was presented by DDP co-chairman Peter Kramer, executive director for Technology Transactions at BMS, to Dr Gary Liversidge, Elan Drug Technologies’ chief technology officer and one of the key inventors of the NanoCrystal technology platform. This meeting is a leading worldwide event for personnel engaged in leading pipeline expansion through drug delivery innovation.
Date: February 5, 2010
Source: Elan Drug Technologies
